

Silvia Stacchiotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3229958/publications.pdf>

Version: 2024-02-01

246
papers

15,157
citations

13827

67
h-index

22102

113
g-index

246
all docs

246
docs citations

246
times ranked

10350
citing authors

#	ARTICLE	IF	CITATIONS
1	Soft tissue and visceral sarcomas: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
2	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 595-602.	5.1	416
3	Gastrointestinal stromal tumours: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
4	Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 24-30.	0.8	410
5	Bone sarcomas: ESMOâ€“PaedCanâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
6	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2017, 18, 812-822.	5.1	370
7	Building a global consensus approach to chordoma: a position paper from the medical and patient community. <i>Lancet Oncology</i> , The, 2015, 16, e71-e83.	5.1	367
8	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 671-680.	5.1	318
9	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PATients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	0.6	274
10	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet</i> , The, 2019, 394, 478-487.	6.3	273
11	Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution. <i>Annals of Surgery</i> , 2010, 251, 506-511.	2.1	253
12	Imatinib mesylate in chordoma. <i>Cancer</i> , 2004, 101, 2086-2097.	2.0	250
13	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	1.3	243
14	Phase II Study of Imatinib in Advanced Chordoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 914-920.	0.8	230
15	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012, 118, 1649-1655.	2.0	222
16	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii113-iii123.	0.6	212
17	High-Grade Soft-Tissue Sarcomas: Tumor Response Assessmentâ€“Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria. <i>Radiology</i> , 2009, 251, 447-456.	3.6	198
18	Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1423-1432.	5.1	194

#	ARTICLE	IF	CITATIONS
19	Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. <i>Annals of Oncology</i> , 2011, 22, 1682-1690.	0.6	185
20	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. <i>Annals of Oncology</i> , 2012, 23, 1067-1073.	0.6	180
21	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017, 28, 1230-1242.	0.6	168
22	Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers. <i>Annals of Surgical Oncology</i> , 2010, 17, 211-219.	0.7	159
23	Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). <i>European Journal of Surgical Oncology</i> , 2009, 35, 739-745.	0.5	156
24	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	0.8	156
25	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 1447-1454.	0.7	152
26	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncologica</i> , 2017, 56, 88-92.	0.8	146
27	Myxoid/round cell and pleomorphic liposarcomas. <i>Cancer</i> , 2007, 109, 2522-2531.	2.0	145
28	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	0.8	145
29	Chordoma. <i>Current Opinion in Oncology</i> , 2007, 19, 367-370.	1.1	144
30	Response to imatinib plus sirolimus in advanced chordoma. <i>Annals of Oncology</i> , 2009, 20, 1886-1894.	0.6	142
31	Sunitinib malate in solitary fibrous tumor (SFT). <i>Annals of Oncology</i> , 2012, 23, 3171-3179.	0.6	140
32	Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma. <i>Clinical Cancer Research</i> , 2009, 15, 1096-1104.	3.2	138
33	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 3531-3540.	0.7	136
34	Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. <i>Clinical Cancer Research</i> , 2006, 12, 6920-6928.	3.2	135
35	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 1308 trial). <i>Lancet Respiratory Medicine</i> , 2018, 6, 431-441.	0.784314	134
36	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. <i>European Journal of Cancer</i> , 2019, 109, 51-60.	1.3	134

#	ARTICLE	IF	CITATIONS
37	Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. <i>European Journal of Cancer</i> , 2015, 51, 186-192.	1.3	133
38	Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. <i>Annals of Oncology</i> , 2012, 23, 501-508.	0.6	130
39	Synovial Sarcoma: Current Concepts and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2018, 36, 180-187.	0.8	129
40	Phase II study on lapatinib in advanced EGFR-positive chordoma. <i>Annals of Oncology</i> , 2013, 24, 1931-1936.	0.6	122
41	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	0.7	105
42	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 383-393.	2.1	101
43	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016, 53, 84-95.	1.3	99
44	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. <i>European Journal of Cancer</i> , 2015, 51, 210-217.	1.3	97
45	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 134-144.	5.1	97
46	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
47	Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. <i>Cancer</i> , 2010, 116, 2429-2436.	2.0	93
48	High-grade Sarcomatous Overgrowth in Solitary Fibrous Tumors. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1202-1215.	2.1	91
49	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288.	0.6	90
50	Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. <i>Neuro-Oncology</i> , 2010, 12, 776-789.	0.6	88
51	Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution. <i>Annals of Surgical Oncology</i> , 2010, 17, 3229-3233.	0.7	87
52	Resectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1064-1070.	0.5	86
53	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
54	Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. <i>European Journal of Cancer</i> , 2006, 42, 1484-1490.	1.3	85

#	ARTICLE	IF	CITATIONS
55	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	2.0	85
56	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561.		85
57	Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1286-1297.	1.9	83
58	Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. <i>Clinical Sarcoma Research</i> , 2013, 3, 4.	2.3	81
59	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 639-648.	5.1	81
60	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	1.3	80
61	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016, 6, 15.	2.3	80
62	Imatinib in advanced chordoma: A retrospective case series analysis. <i>European Journal of Cancer</i> , 2015, 51, 2609-2614.	1.3	78
63	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). <i>Clinical Cancer Research</i> , 2016, 22, 837-846.	3.2	78
64	Response to chemotherapy of solitary fibrous tumour: A retrospective study. <i>European Journal of Cancer</i> , 2013, 49, 2376-2383.	1.3	77
65	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 877-886.	5.1	75
66	Activity of sunitinib in extraskeletal myxoid chondrosarcoma. <i>European Journal of Cancer</i> , 2014, 50, 1657-1664.	1.3	74
67	Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. <i>Spine</i> , 2016, 41, 1049-1057.	1.0	74
68	Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 86-91.	1.0	71
69	Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. <i>BMC Medicine</i> , 2017, 15, 109.	2.3	71
70	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 "CREATE". <i>Annals of Oncology</i> , 2017, 28, 3000-3008.	0.6	70
71	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone " Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1384-1390.	0.5	70
72	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019, 25, 5295-5300.	3.2	70

#	ARTICLE	IF	CITATIONS
73	Chordoma: update on disease, epidemiology, biology and medical therapies. <i>Current Opinion in Oncology</i> , 2019, 31, 114-120.	1.1	70
74	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , 2013, 24, 817-823.	0.6	69
75	Dermatofibrosarcoma protuberansâ€derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib. <i>International Journal of Cancer</i> , 2011, 129, 1761-1772.	2.3	68
76	Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-Ã-vis Temozolomide and Antiangiogenics. <i>Clinical Cancer Research</i> , 2013, 19, 5192-5201.	3.2	67
77	Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. <i>Modern Pathology</i> , 2015, 28, 1074-1083.	2.9	67
78	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 â€CREATEâ€™. <i>Annals of Oncology</i> , 2018, 29, 758-765.	0.6	67
79	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	2.0	65
80	Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. <i>Annals of Oncology</i> , 2013, 24, 2181-2189.	0.6	63
81	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
82	Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 603-613.	1.9	63
83	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	1.9	62
84	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371.	5.1	61
85	Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. <i>European Journal of Cancer</i> , 2015, 51, 2800-2807.	1.3	58
86	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1252-1262.	5.1	57
87	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 2735-2744.	0.7	56
88	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. <i>European Journal of Cancer</i> , 2018, 105, 19-27.	1.3	56
89	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	1.5	53
90	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 456-466.	5.1	51

#	ARTICLE	IF	CITATIONS
91	Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. <i>European Journal of Cancer</i> , 2014, 50, 3021-3028.	1.3	50
92	Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11003-11003.	0.8	50
93	Emerging therapies for adult soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 689-704.	1.1	49
94	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 93, 28-36.	1.3	49
95	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG–STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	2.0	46
96	Medical treatment of advanced chordomas. <i>European Journal of Cancer</i> , 2017, 83, 220-228.	1.3	45
97	Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. <i>European Journal of Cancer</i> , 2007, 43, 601-606.	1.3	44
98	Systemic Therapy Options for Unresectable and Metastatic Chordomas. <i>Current Oncology Reports</i> , 2011, 13, 323-330.	1.8	42
99	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-1 or -2. <i>Cancer</i> , 2011, 117, 826-831.	2.0	42
100	Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. <i>Annals of Oncology</i> , 2011, 22, 1675-1681.	0.6	42
101	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	3.2	42
102	Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. <i>Surgical Oncology</i> , 2016, 25, 125-131.	0.8	41
103	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. <i>Oncolmunology</i> , 2019, 8, e1617588.	2.1	41
104	Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. <i>Cancer</i> , 2018, 124, 4056-4063.	2.0	40
105	Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. <i>Frontiers in Oncology</i> , 2018, 8, 449.	1.3	39
106	Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1226-1233.	0.4	39
107	Extrameningeal solitary fibrous tumorsâ€”surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. <i>Cancer</i> , 2020, 126, 3002-3012.	2.0	39
108	Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. <i>Clinical Sarcoma Research</i> , 2013, 3, 8.	2.3	38

#	ARTICLE	IF	CITATIONS
109	<scp>HSPA</scp>8 as a novel fusion partner of <scp>NR</scp>4<scp>A</scp>3 in extraskeletal myxoid chondrosarcoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 582-586.	1.5	38
110	Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. <i>Journal of Pathology</i> , 2007, 212, 227-235.	2.1	37
111	Tumor response to sunitinib malate observed in clear-cell sarcoma. <i>Annals of Oncology</i> , 2010, 21, 1130-1131.	0.6	37
112	(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. <i>European Journal of Cancer</i> , 2017, 70, 1-11.	1.3	37
113	Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor. <i>Pediatric Blood and Cancer</i> , 2007, 49, 864-866.	0.8	36
114	Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1662-1670.	0.5	36
115	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11057-11057.	0.8	36
116	Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. <i>Clinical Sarcoma Research</i> , 2013, 3, 16.	2.3	34
117	Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. <i>European Journal of Cancer</i> , 2019, 106, 225-233.	1.3	32
118	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 249-259.	1.9	30
119	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019, 101, 1309-1318.	1.4	30
120	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. <i>Journal of Investigative Dermatology</i> , 2017, 137, 484-493.	0.3	29
121	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , 2021, 127, 884-893.	2.0	29
122	β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. <i>Molecular Oncology</i> , 2017, 11, 1495-1507.	2.1	28
123	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021, 26, e863-e873.	1.9	28
124	Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. <i>Clinical Sarcoma Research</i> , 2012, 2, 22.	2.3	27
125	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018, 23, 461-467.	1.9	27
126	NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. <i>Journal of Pathology</i> , 2019, 249, 90-101.	2.1	27

#	ARTICLE	IF	CITATIONS
127	Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management. <i>Cancers</i> , 2020, 12, 2703.	1.7	27
128	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020, 25, e1777-e1784.	1.9	27
129	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. <i>European Journal of Cancer</i> , 2017, 76, 84-92.	1.3	26
130	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. <i>European Journal of Cancer</i> , 2021, 156, 12-23.	1.3	26
131	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelialâ€“Mesenchymal Transitionâ€“like Process and 22q Loss. <i>Molecular Cancer Research</i> , 2016, 14, 820-829.	1.5	25
132	The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelialâ€“mesenchymal transition, and immune response. <i>Cancer Communications</i> , 2018, 38, 1-14.	3.7	25
133	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	2.0	25
134	Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A caseâ€“series analysis within the Italian Rare Cancer Network. <i>Cancer</i> , 2021, 127, 569-576.	2.0	24
135	Confusion after antibiotics. <i>Lancet, The</i> , 2001, 357, 1410.	6.3	23
136	Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 1142-1150.	0.7	23
137	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23
138	Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. <i>British Journal of Cancer</i> , 2007, 96, 180-181.	2.9	22
139	Receptor tyrosine kinase pathway analysis sheds light on similarities between clearâ€“cell sarcoma and metastatic melanoma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 111-126.	1.5	22
140	Outcome of ilio caval resection and reconstruction for retroperitoneal sarcoma. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2019, 7, 547-556.	0.9	22
141	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020, 5, e000787.	2.0	22
142	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. <i>British Journal of Cancer</i> , 2014, 111, 1350-1362.	2.9	21
143	Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. <i>Cancers</i> , 2019, 11, 1015.	1.7	21
144	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11058-11058.	0.8	21

#	ARTICLE	IF	CITATIONS
145	A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4027-4032.	3.2	21
146	Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. <i>British Journal of Cancer</i> , 2017, 117, 340-346.	2.9	20
147	Epithelioid angiosarcoma of the thyroid gland without distant metastases at diagnosis: report of six cases with a long follow-up. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 223-232.	1.4	19
148	Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. <i>Journal of Immunology Research</i> , 2018, 2018, 1-13.	0.9	19
149	Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study. <i>International Journal of Cancer</i> , 2011, 128, 983-990.	2.3	18
150	Targeted Therapies in Rare Sarcomas. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1049-1061.	0.9	18
151	Novel intra-genic large deletions of <i>CTNNB1</i> gene identified in WT desmoid-type fibromatosis. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 495-503.	1.5	18
152	Pharmacological therapies for Liposarcoma. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 361-377.	1.3	17
153	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. <i>Oncotarget</i> , 2017, 8, 60036-60045.	0.8	17
154	The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1320-1326.	0.5	17
155	Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. <i>Future Oncology</i> , 2021, 17, 1253-1263.	1.1	17
156	Localised thoracic sarcomas: Outcome improvement over time at a single institution. <i>European Journal of Cancer</i> , 2013, 49, 2689-2697.	1.3	16
157	Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2016, 21, 361-369.	0.3	16
158	Unplanned Excision of Extremity and Trunk Wall Soft Tissue Sarcoma: To Re-resect or Not to Re-resect?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4706-4717.	0.7	16
159	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11502-11502.	0.8	16
160	Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. <i>Modern Pathology</i> , 2020, 33, 217-227.	2.9	15
161	Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review. <i>ESMO Open</i> , 2020, 5, e000663.	2.0	15
162	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15

#	ARTICLE	IF	CITATIONS
163	Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. <i>BMC Cancer</i> , 2015, 15, 58.	1.1	14
164	Establishment and genomic characterization of the new chordoma cell line Chor-IN-1. <i>Scientific Reports</i> , 2017, 7, 9226.	1.6	14
165	New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs). <i>Oncotarget</i> , 2017, 8, 32492-32504.	0.8	14
166	Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. <i>Neuro-Oncology</i> , 2014, 16, 72-80.	0.6	13
167	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021, 92, 493-499.	1.2	13
168	Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours. <i>Oncotarget</i> , 2016, 7, 45015-45026.	0.8	13
169	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	0.7	13
170	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	2.0	11
171	Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin downregulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 83.	3.5	11
172	Neoadjuvant treatment: a novel standard?. <i>Current Opinion in Oncology</i> , 2017, 29, 253-259.	1.1	10
173	Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor. <i>Anti-Cancer Drugs</i> , 2018, 29, 589-595.	0.7	10
174	Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3535-3541.	0.7	10
175	Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1723-1729.	0.5	10
176	Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients: A propensity score analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 318-323.	0.8	9
177	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 132-141.	1.9	9
178	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial. <i>Cancers</i> , 2021, 13, 6057.	1.7	9
179	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 480-492.	1.0	8
180	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 154, 253-268.	1.3	8

#	ARTICLE	IF	CITATIONS
181	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. Journal of Clinical Oncology, 2013, 31, 10516-10516.	0.8	8
182	IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypesâ€”Results of the phase I part.. Journal of Clinical Oncology, 2018, 36, 11515-11515.	0.8	8
183	Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor. Expert Review of Anticancer Therapy, 2022, 22, 491-503.	1.1	8
184	Response of conventional chondrosarcoma to gemcitabine alone: a case report. Clinical Sarcoma Research, 2015, 5, 9.	2.3	7
185	The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. Expert Review of Anticancer Therapy, 2016, 16, 473-484.	1.1	7
186	Exposureâ€”response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1422-1432.	1.3	7
187	<scp>CINSARC</scp> in highâ€”risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <scp>ISCâ€”STS</scp> 1001 study. Cancer Medicine, 2023, 12, 1350-1357.	1.3	7
188	Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma. Journal of Translational Medicine, 2013, 11, 237.	1.8	6
189	How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clinical Sarcoma Research, 2017, 7, 4.	2.3	6
190	High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. Sarcoma, 2017, 2017, 1-5.	0.7	6
191	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. Oncologist, 2020, 25, e1562-e1573.	1.9	6
192	Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. Expert Review of Clinical Pharmacology, 2020, 13, 571-576.	1.3	6
193	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Review of Anticancer Therapy, 2020, 20, 15-28.	1.1	6
194	Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoidâ€”type fibromatosis. Cancer Medicine, 2021, 10, 4356-4365.	1.3	6
195	Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review. Clinical Sarcoma Research, 2016, 6, 16.	2.3	5
196	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. Journal of Clinical Oncology, 2017, 35, TPS11081-TPS11081.	0.8	5
197	Prognostic stratification using the nomogram sarculator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931.. Journal of Clinical Oncology, 2018, 36, 11518-11518.	0.8	5
198	Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. Annals of Surgical Oncology, 2022, 29, 3274-3286.	0.7	5

#	ARTICLE	IF	CITATIONS
199	Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective caseâ€series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448.	2.0	5
200	Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States. <i>Hpb</i> , 2022, 24, 1688-1696.	0.1	5
201	Review of past and present clinical cases with a view to future treatment options. <i>Future Oncology</i> , 2017, 13, 11-28.	1.1	4
202	Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. <i>BMC Medicine</i> , 2017, 15, 160.	2.3	4
203	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1855.	1.8	4
204	A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11018-11018.	0.8	4
205	Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11042-11042.	0.8	4
206	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. <i>European Journal of Cancer</i> , 2022, 171, 183-192.	1.3	4
207	Leiomyosarcoma and sarcoma with myogenic differentiation. <i>Cancer</i> , 2012, 118, 5349-5357.	2.0	3
208	Contributions of Real-World Evidence and Real-World Data to Decision-Making in the Management of Soft Tissue Sarcomas. <i>Oncology</i> , 2021, 99, 3-7.	0.9	3
209	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10006-10006.	0.8	3
210	Sunitinib malate in advanced alveolar soft part sarcoma (ASPS): A final update after the closure of the named use program.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10562-10562.	0.8	3
211	Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11003-11003.	0.8	3
212	International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11062-11062.	0.8	3
213	Effect of Mild and Moderate Hepatic Impairment (Defined by Childâ€Pugh Classification and National) Tj ETQq1 1 0.784314 rgBT /Over <i>Journal of Clinical Pharmacology</i> , 2022, 62, 992-1005.	1.0	3
214	Firstâ€line chemotherapy in advanced intraâ€abdominal wellâ€differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Cancer</i> , 2022, 128, 2932-2938.	2.0	3
215	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-ST5 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	1.9	2
216	Extraskeletal myxoid chondrosarcoma: A retrospective analysis of 69 patients with localized disease and molecularly confirmed diagnosis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10589-10589.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Doxorubicin plus dacarbazine (DTIC) in advanced solitary fibrous tumor (SFT): An Italian retrospective case series analysis.. Journal of Clinical Oncology, 2016, 34, 11042-11042.	0.8	2
218	Neoadjuvant denosumab treatment of locally advanced giant cell tumor of bone (GCTB).. Journal of Clinical Oncology, 2017, 35, 11026-11026.	0.8	2
219	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. Journal of Clinical Oncology, 2017, 35, 11065-11065.	0.8	2
220	First prospective observational study in diffuse-type tenosynovial giant cell tumors.. Journal of Clinical Oncology, 2018, 36, 11560-11560.	0.8	2
221	Worsening Hemoptysis in a Rare Intrapulmonary Triton Tumor Mimicking Lung Cancer. Annals of Thoracic Surgery, 2020, 109, e199-e201.	0.7	1
222	Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-up of an exploratory analysis on a phase III trial.. Journal of Clinical Oncology, 2016, 34, 11044-11044.	0.8	1
223	Sunitinib (SM) in advanced extraskeletal myxoid chondrosarcoma (EMC): Updated analysis in 11 patients (pts).. Journal of Clinical Oncology, 2016, 34, 11059-11059.	0.8	1
224	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2018, 36, 11534-11534.	0.8	1
225	Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.. Journal of Clinical Oncology, 2019, 37, e18236-e18236.	0.8	1
226	The Impact of Chemotherapy on Survival of Patients with Extremity and Trunk Wall Soft Tissue Sarcoma: Revisiting the Results of the EORTC-STBSG 62931 Randomised Trial Using Sarculator, a Validated Nomogram-Based Risk Assessment Tool. SSRN Electronic Journal, 0, , .	0.4	1
227	Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile.. Journal of Clinical Oncology, 2015, 33, 10553-10553.	0.8	1
228	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 11540-11540.	0.8	1
229	Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. Cancers, 2022, 14, 2624.	1.7	1
230	Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature. Frontiers in Oncology, 0, 12, .	1.3	1
231	Cediranib for alveolar soft part sarcoma: a randomised study in relation to clinical practice. Lancet Oncology, The, 2019, 20, 901-903.	5.1	0
232	In Reply. Oncologist, 2020, 25, e2018.	1.9	0
233	Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals. Cancer, 2020, 126, 4615-4616.	2.0	0
234	ASO Author Reflections: Extraskeletal Myxoid Chondrosarcoma: A Rare Sarcoma Associated With Prolonged Survival. Annals of Surgical Oncology, 2020, 27, 797-798.	0.7	0

#	ARTICLE	IF	CITATIONS
235	Reply to Incidence of extrameningeal solitary fibrous tumors and Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy. <i>Cancer</i> , 2020, 126, 4069-4070.	2.0	0
236	Activity of chemotherapy in a series of patients with locally advanced or metastatic pleomorphic rhabdomyosarcoma: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10592-10592.	0.8	0
237	Malignancy grade and immunohistochemical myogenic/rhabdomyoblastic differentiation as an outcome determinant in retroperitoneal liposarcoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10588-10588.	0.8	0
238	Primary epithelioid angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10578-10578.	0.8	0
239	Natural history and outcome in a large series of primary dermatofibrosarcoma protuberans (DFSP) treated at a reference institution.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10554-10554.	0.8	0
240	Abstract 1086: CTNNB1-mutated desmoid tumors have different gene expression patterns compared to wild-type ones. , 2015, , .		0
241	Abstract 74: Establishment and characterization of the new sacral chordoma cell line Chor-IN-1. , 2015, , .		0
242	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11045-11045.	0.8	0
243	Solitary fibrous tumour relapsing with a single bone metastasis: Report of five cases.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22525-e22525.	0.8	0
244	Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11062-11062.	0.8	0
245	Short, full-dose neoadjuvant chemotherapy in localized high-risk adult soft tissue sarcomas (STS): An exploratory subgroup analysis on responding patients in a randomized controlled trial comparing 3 neoadjuvant versus 3 neoadjuvant + 2 adjuvant cycles of full dose anthracycline and ifosfamide chemotherapy at a 10yr median FU.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11558-11558.	0.8	0
246	Characterization of tumor microenvironment in extraskeletal myxoid chondrosarcoma (EMC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11561-11561.	0.8	0